Cytidine deaminase expression level in cancer as a new therapeutic target - Archive ouverte HAL Accéder directement au contenu
Brevet Année : 2017

Cytidine deaminase expression level in cancer as a new therapeutic target

Résumé

The present invention provides an in vitro method for selecting a patient affected with a tumor for a treatment with an antitumor compound, wherein the method comprises a step of measuring the expression level of CDA (Cytidine Deaminase) in a cancer sample from said patient. When the CDA expression level of a cancer sample is lower than the reference expression level, it is indicative that the patient is suitable for a treatment with an antitumor compound selected from the group consisting of the compounds of table 4, in particular aminoflavone. Alternatively, when the CDA expression level of a cancer sample is higher than the reference expression level, it is indicative that the patient is suitable for a treatment with an antitumor compound selected from the group consisting of the compounds of table 3, in particular dasatinib.
Fichier non déposé

Dates et versions

hal-02786497 , version 1 (05-06-2020)

Identifiants

  • HAL Id : hal-02786497 , version 1
  • PRODINRA : 444638

Citer

Mounira Amor-Guéret, Hamza Mameri. Cytidine deaminase expression level in cancer as a new therapeutic target. Patent n° : WO2017EP57752 20170331. 2017. ⟨hal-02786497⟩

Collections

CNRS INRAE
15 Consultations
0 Téléchargements

Partager

Gmail Facebook X LinkedIn More